Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
Strange time. It may be just a delay. But dare we start to dream that the “interested parties” that Tim has mentioned in past RNS announcements have now come knocking on his door? Always remember that dreams do not often come true!
Tim has been stating that they have been in ongoing discussions with interested parties for a long time now. Wonder if they actually received one or more offers during this time that were rejected- so no RNS needed? Guess we would only find out if we were to finally get a takeover.
There has been a number of chunky buys for the last couple of weeks now. Why invest at this time when it is uncertain about the outcome of the trial application and the process has gone above the normal 60 days target for publication? If the CTA announcement does not happen tomorrow or during next week and the big buys continue, then the rumour mill may start to go into overdrive.
Blastoid - Sierra Oncology had a number of offers before agreeing to the final one. It was only then that an RNS was issued. So I assume that the same applies to Sareum - ie offers the Board feel are unacceptable would not trigger an RNS.
Nice find alithoth. Seems the antibodies in long covid are similar to those found in arthritis and lupus patients. 1801 may be just the ticket for long Covid. Sure Tim will be on the case as he is keen to test 1801 in this area. Yet another possible string to our bow.
Sad - great find on the Patent applications by Sierra Oncology dated 16/6/22 and 21/7/22 Entitled ‘ Method of treating Cancer using CHK1 inhibitors” which refers to SRA 737 with Gemcitibane and SRA 737 with other combinations. It is long but there is some very exciting reading as well. The reference to the number of Cancers that can be treated is breathtaking - as many on this Board have stated for some time. I am sure that most regular posters will study at least some of the detail but I would urge other investors to do so also. It shows that SRA737 is at last about to come into the limelight in a big way. Very exciting.
Hi Potnak - agree everyone is entitled to their views. I am trying to work out the role of Peel Hunt. Do you think that PH was appointed by Sareum with a two to four year strategy in mind? Do you think PH clients are the type to find that timescale attractive? All comments welcome .
Hi Utah, for once I can agree with you that it is not a leak and as far as I am concerned it is nothing to do with SRA 737. I refer you to Aber’s post earlier today which I concur with. Do you? It is not ‘normal trading’ compared to what we have been seeing over recent months.
Tim and John are not getting any younger. I think the HNIWs were the drivers behind the Peel Hunt deal. Could be wrong but do not think they would want a succession of deals. To me separate licences for SDC1801 and SDC 1802 is messy. I myself am expecting the Peel Hunt role to secure a takeover at early clinical stage. I think most on this Board would much prefer that.
The marketing of TYK2 is a game changing moment. No or few black box issues. Covers extensive autoimmune and Cancer conditions. If SDC-01 with its Jak1 passes the low toxicity requirements in phase A then I think it will be takeover time as SDC-1802 has a similar profile. I do not think that Peel Hunt would want to be waiting two years to get an agreement. They have been told the strategy. The management of the share price suggests to me that we are moving closer to the end game.
As Potnak says,we all are entitled to our views. GLA
PCS - regarding Sareum risk element - let’s not forget that the risk is greatly reduced with the Sareum strategy of licensing pre-clinical or early clinical as we will have an upfront payment - bigger the better!